Lennox-Gastaut%252520syndrome

# Lennox-Gastaut Syndrome (LGS) ## Overview LGS is a severe form of childhood-onset epilepsy characterized by multiple seizure types, intellectual disability, and slow spike-and-wave EEG patterns. Treatment is often refractory, requiring polytherapy with agents specifically approved for LGS. ## Primary Indications Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome. ## Adult Dosing * **Rufinamide:** Start 400–800 mg/day in two divided doses. Increase by 400–800 mg/day every 2 days to max 3,200 mg/day. * **Clobazam:** Start 5–10 mg/day, titrated to 20 mg/day (for patients >30 kg) over 2 weeks. * **Cannabidiol (CBD):** Start 2.5 mg/kg twice daily (5 mg/kg/day); after 1 week, increase to 5 mg/kg twice daily (10 mg/kg/day). * **Felbamate:** Start 1,200 mg/day in 3–4 divided doses; increase by 600 mg every week to max 3,600 mg/day. ## Pediatric Dosing * **Rufinamide (1+ year):** Start 10 mg/kg/day in two divided doses. Increase by 10 mg/kg/day every 2 days to max 45 mg/kg/day (up to 3,200 mg/day). * **Clobazam (2+ years):** * ≤30 kg: Start 5 mg/day; titrate to 10 mg/day. * >30 kg: Start 10 mg/day; titrate to 20 mg/day. * **Cannabidiol (1+ year):** 2.5 mg/kg twice daily; increase to 5 mg/kg twice daily (10 mg/kg/day). Can titrate to 10 mg/kg twice daily (20 mg/kg/day) based on tolerance. * **Topiramate (2+ years):** 5–9 mg/kg/day in two divided doses. * **Lamotrigine:** Requires slow initiation due to SJS risk; dosing is highly dependent on concomitant enzyme-inducing AEDs (e.g., valproate requires 50% dose reduction). ## Dose Adjustments * **Renal/Hepatic:** Reduce starting doses for felbamate and clobazam in severe impairment. Refer to specific manufacturer labeling for creatinine clearance-based adjustments. * **Drug-Drug:** Valproate significantly increases serum concentrations of lamotrigine and clobazam (via CYP2C19 inhibition); require dose reductions. ## Contraindications * **Rufinamide:** Familial Short QT syndrome. * **Felbamate:** History of aplastic anemia or severe hepatic impairment. * **Cannabidiol:** Hypersensitivity to cannabinoids. ## Adverse Effects * **General:** Somnolence, dizziness, fatigue, ataxia, and weight loss. * **Specific:** * *Felbamate:* Aplastic anemia, hepatotoxicity (requires baseline/periodic LFTs and CBC). * *Rufinamide:* Shortened QT interval. * *CBD:* Transaminase elevations, diarrhea, decreased appetite. * *Topiramate:* Cognitive impairment, nephrolithiasis, metabolic acidosis. ## Key Drug Interactions * **CYP450 Inducers (e.g., Phenytoin, Carbamazepine):** Decrease levels of clobazam, rufinamide, and topiramate. * **CYP450 Inhibitors (e.g., Valproate):** Increase levels of clobazam (specifically its active metabolite N-desmethylclobazam). * **CNS Depressants:** Exacerbate sedation when combined with benzodiazepines (Clobazam). ## Monitoring * **Baseline/Routine:** CBC and LFTs for agents with rare but serious organ toxicity (Felbamate, CBD). * **ECG:** Recommended for patients on Rufinamide if history of cardiac conduction issues. * **Serum Levels:** Therapeutic Drug Monitoring (TDM) is useful for valproate, phenytoin, or carbamazepine if used adjunctively, though less standardized for newer agents like CBD. ## Clinical Pearls * **Ketogenic Diet:** Often utilized as a non-pharmacological mainstay for LGS when drug therapy fails. * **Clobazam:** Rapid tolerance to anticonvulsant effects can occur; monitor for breakthrough seizures. * **Titration:** Always prioritize the "start low, go slow" principle to minimize cognitive and behavioral side effects, which are prevalent in the LGS population. * **Note:** Exact dosing protocols may vary by epilepsy center; always consult local institutional guidelines for rescue medication protocols (e.g., buccal midazolam or rectal diazepam). *** **Educational Disclaimer:** This information is for educational purposes only. Clinical practice varies by institution and patient-specific factors. Always verify current FDA-approved prescribing information and local hospital protocols before dosing.